Cargando…

What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice Experiment

Several treatment options are available for chronic lymphocytic leukemia (CLL) and, for this reason, treatment choice can result challenging after introducing oral targeted agents. This study aims at comparing patients’ and hematologists’ preferences for attributes of CLL treatments. An online cross...

Descripción completa

Detalles Bibliográficos
Autores principales: Laurenti, Luca, Gaidano, Gianluca, Mauro, Francesca Romana, Molica, Stefano, Pasqualetti, Patrizio, Scarfò, Lydia, Ghia, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436277/
https://www.ncbi.nlm.nih.gov/pubmed/36081648
http://dx.doi.org/10.1097/HS9.0000000000000771
_version_ 1784781324077236224
author Laurenti, Luca
Gaidano, Gianluca
Mauro, Francesca Romana
Molica, Stefano
Pasqualetti, Patrizio
Scarfò, Lydia
Ghia, Paolo
author_facet Laurenti, Luca
Gaidano, Gianluca
Mauro, Francesca Romana
Molica, Stefano
Pasqualetti, Patrizio
Scarfò, Lydia
Ghia, Paolo
author_sort Laurenti, Luca
collection PubMed
description Several treatment options are available for chronic lymphocytic leukemia (CLL) and, for this reason, treatment choice can result challenging after introducing oral targeted agents. This study aims at comparing patients’ and hematologists’ preferences for attributes of CLL treatments. An online cross-sectional survey has been delivered to clinicians and patients affected by CLL in Italy. A discrete choice experiment has been conducted so to estimate each attribute’s relative importance (RI) and assess the preference weight for each level of each attribute. An expert panel agreed on investigating the following attributes: progression-free survival (PFS) and measurable residual disease, route of administration/therapy duration and follow-up frequency, incidence of diarrhea (episodes/day), serious infections (grade 3 or 4), and atrial fibrillation. Overall, 746 patients and 109 clinicians accessed the survey, and 215 and 69, respectively, filled it in. The most important attributes were PFS (RI 30%) for hematologists and the risk of severe infections (RI 24%) for patients. Clinicians rated preference for maximum efficacy and lowest risk of severe infection very high (30%). Both patients and clinicians preferred oral administration while considering duration of therapy less relevant. The frequency of hospital appointments was negligible for patients, while clinicians preferred a quarterly frequency. Considering all attributes, diarrhea was weighted more by clinicians than by patients. Atrial fibrillation was not relevant for clinicians, while it was not negligible for patients. In conclusion, clinicians and patients favor an oral therapy, including continuous treatment, if associated with prolonged PFS, albeit with particular attention to the risk of serious infections.
format Online
Article
Text
id pubmed-9436277
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94362772022-09-07 What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice Experiment Laurenti, Luca Gaidano, Gianluca Mauro, Francesca Romana Molica, Stefano Pasqualetti, Patrizio Scarfò, Lydia Ghia, Paolo Hemasphere Article Several treatment options are available for chronic lymphocytic leukemia (CLL) and, for this reason, treatment choice can result challenging after introducing oral targeted agents. This study aims at comparing patients’ and hematologists’ preferences for attributes of CLL treatments. An online cross-sectional survey has been delivered to clinicians and patients affected by CLL in Italy. A discrete choice experiment has been conducted so to estimate each attribute’s relative importance (RI) and assess the preference weight for each level of each attribute. An expert panel agreed on investigating the following attributes: progression-free survival (PFS) and measurable residual disease, route of administration/therapy duration and follow-up frequency, incidence of diarrhea (episodes/day), serious infections (grade 3 or 4), and atrial fibrillation. Overall, 746 patients and 109 clinicians accessed the survey, and 215 and 69, respectively, filled it in. The most important attributes were PFS (RI 30%) for hematologists and the risk of severe infections (RI 24%) for patients. Clinicians rated preference for maximum efficacy and lowest risk of severe infection very high (30%). Both patients and clinicians preferred oral administration while considering duration of therapy less relevant. The frequency of hospital appointments was negligible for patients, while clinicians preferred a quarterly frequency. Considering all attributes, diarrhea was weighted more by clinicians than by patients. Atrial fibrillation was not relevant for clinicians, while it was not negligible for patients. In conclusion, clinicians and patients favor an oral therapy, including continuous treatment, if associated with prolonged PFS, albeit with particular attention to the risk of serious infections. Lippincott Williams & Wilkins 2022-08-31 /pmc/articles/PMC9436277/ /pubmed/36081648 http://dx.doi.org/10.1097/HS9.0000000000000771 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Article
Laurenti, Luca
Gaidano, Gianluca
Mauro, Francesca Romana
Molica, Stefano
Pasqualetti, Patrizio
Scarfò, Lydia
Ghia, Paolo
What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice Experiment
title What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice Experiment
title_full What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice Experiment
title_fullStr What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice Experiment
title_full_unstemmed What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice Experiment
title_short What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice Experiment
title_sort what are the attributes prioritized in the choice of therapy in chronic lymphocytic leukemia? a patient-physician cross-matching analysis of a discrete choice experiment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436277/
https://www.ncbi.nlm.nih.gov/pubmed/36081648
http://dx.doi.org/10.1097/HS9.0000000000000771
work_keys_str_mv AT laurentiluca whataretheattributesprioritizedinthechoiceoftherapyinchroniclymphocyticleukemiaapatientphysiciancrossmatchinganalysisofadiscretechoiceexperiment
AT gaidanogianluca whataretheattributesprioritizedinthechoiceoftherapyinchroniclymphocyticleukemiaapatientphysiciancrossmatchinganalysisofadiscretechoiceexperiment
AT maurofrancescaromana whataretheattributesprioritizedinthechoiceoftherapyinchroniclymphocyticleukemiaapatientphysiciancrossmatchinganalysisofadiscretechoiceexperiment
AT molicastefano whataretheattributesprioritizedinthechoiceoftherapyinchroniclymphocyticleukemiaapatientphysiciancrossmatchinganalysisofadiscretechoiceexperiment
AT pasqualettipatrizio whataretheattributesprioritizedinthechoiceoftherapyinchroniclymphocyticleukemiaapatientphysiciancrossmatchinganalysisofadiscretechoiceexperiment
AT scarfolydia whataretheattributesprioritizedinthechoiceoftherapyinchroniclymphocyticleukemiaapatientphysiciancrossmatchinganalysisofadiscretechoiceexperiment
AT ghiapaolo whataretheattributesprioritizedinthechoiceoftherapyinchroniclymphocyticleukemiaapatientphysiciancrossmatchinganalysisofadiscretechoiceexperiment